Telaprevir

Type: Keyphrase
Name: Telaprevir
First reported Aug 15 2014 - Updated Aug 15 2014 - 1 reports

Interactions with Hepatitis C Antivirals

John R. Horn, PharmD, FCCP, and Philip D. Hansten, PharmDOver the past few years, several new antiviral drugs have been added to the therapeutic options for HCV, including boceprevir, telaprevir, simeprevir, and sofosbuvir. These new therapies have several ... [Published Pharmacy Times - Aug 15 2014]
First reported Aug 15 2014 - Updated Aug 15 2014 - 1 reports

East Coast Biotech Roundup: Amicus, Accelerator, Seventh Sense, & More

New York’s biotech scene is getting a jumpstart, and a Seattle startup incubator is getting a second wind in the process. One of biotech’s high fliers in 2014 soared once again. And one local biotech is awaiting some critical data that could make or break ... [Published Xconomy - Aug 15 2014]
First reported Aug 13 2014 - Updated Aug 14 2014 - 3 reports

Vertex to drop hep C drug Incivek following poor sales14-08-2014

Struggling US Biotech firm Vertex Pharmaceuticals (Nasdaq: VRTX) has said it will cease marketing its hepatitis C treatment Incivek (telaprevir) due to declining sales and strong competition in the hepatitis C treatment arena.Three years after being  ... [Published Pharma Letter - Aug 14 2014]
First reported Aug 13 2014 - Updated Aug 13 2014 - 1 reports

Cyclohexane-Fused Octahydroquinolizine Alkaloids from Myrioneuron faberi with Activity against Hepatitis C Virus

Investigation of the alkaloids from Myrioneuron faberi, a plant unique to China, gave four pairs of enantiomers (1–4). (±)-β-Myrifabral A (1) and (±)-α-myrifabral A (2) formed an inseparable mixture of anomers (cluster A), as did (±)-β-myrifabral B (3) ... [Published Journal of Organic Chemistry - Aug 13 2014]
First reported Aug 11 2014 - Updated Aug 11 2014 - 1 reports

Telaprevir resulted in higher SVR in Japanese patients with HCV

Japanese patients with chronic hepatitis C virus genotype 1 treated with telaprevir combined with pegylated interferon alfa-2b and ribavirin achieved a sustained virologic response, according to study results.Researchers, including Naoki Hiramatsu, MD, ... [Published Orthopedics Today - Aug 11 2014]
First reported Aug 08 2014 - Updated Aug 08 2014 - 1 reports

A Hepatitis C Virus Infection Model with Time-Varying Drug Effectiveness: Solution and Analysis

IntroductionChronic hepatitis C virus (HCV) infection affects between 150 and 180 million people world-wide and is a major cause of chronic liver disease, cirrhosis and hepatocellular carcinoma. A number of agents have been approved for treating HCV infection ... [Published Plosone.org - Aug 08 2014]
First reported Aug 04 2014 - Updated Aug 04 2014 - 1 reports

HALLMARK, COSMOS: New HCV regimens show high cure rates

Novel direct-acting antiviral agents were effective in treating infection with hepatitis C virus genotype 1 — even in the hardest-to-treat patients — according to results from two major clinical trials published in the Lancet .The HALLMARK-DUAL and COSMOS ... [Published Orthopedics Today - Aug 04 2014]
First reported Jul 31 2014 - Updated Jul 31 2014 - 1 reports

15 Deaths During Use Of Hep C Drug Telavic Since Japan Launch

Article # 28140730011Posted: Jul. 31, 2014 6:30 AM GMTExecutive SummaryOf the Japanese patients who have been prescribed the hepatitis C drug Telavic (telaprevir) since its launch in 2011, 23% have experienced severe side-effects such as dermatitis and ... [Published Health News Daily - Jul 31 2014]
First reported Jul 31 2014 - Updated Jul 31 2014 - 1 reports

Lack of Clinically Relevant Drug Interactions Between Elvitegravir plus Ritonavir Boosted-Atazanavir and Telaprevir

20th International AIDS ConferenceJuly 20-25, 2014Melbourne, Australia Reported by 20th International AIDS Conference, July 20-25, 2014, MelbourneJM Custodio, S Guo, EB Lawson, H Cao, A Silva, BP Kearney, and S Ramanathan Gilead Sciences, Inc., Foster ... [Published National AIDS Treatment Advocacy Project - Jul 31 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 2 reports

New therapies for HCV create better alternatives for patients

Therapeutic advances in treating hepatitis C virus have greatly increased a patient’s chance for a cure and at a faster rate, according to a consumer update from the FDA.The new report, available on the FDA website, states that interferon injections were ... [Published Orthopedics Today - Jul 28 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 3 reports

The Hepatitis C virus is the main cause of liver transplant in the world

PORT OF SPAIN, Trinidad and TobagoPhoto - http://www2.prnewswire.com.br/imgs/pub/2014-07-25/original/2026.jpgClinical studies show that the regimen of the treatment based in Telaprevir together with pegylated interferon + ribavirin increases the percentage ... [Published Bio-Medicine - Jul 25 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

telaprevir (Incivek)

Pharmacy Author:Omudhome Ogbru, PharmDDr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. ... [Published MedicineNet.com - Jul 22 2014]

Quotes

"We demonstrated that SOF-based TT improves survival compared with first-generation PI-based TT in untreated G1 CHC patients , and that it is cost-effective by assuming a drug price of 3,500 per week. SOF was always, but not in patients with cirrhosis and in IL28B CC patients, cost-effective compared with BOC. SOF was cost-effective compared with TVR in IL28B CT/TT and G1a patients, not cost-effective in IL28B CC, fibrosis F0-F3, and in cirrhosis patients, and dominated in G1b patients. The robustness of these results was confirmed in the probabilistic sensitivity analyses. The cost-effectiveness of SOF was sensitive to SOF price, SVR rate variations of both SOF and first-generation PI, and annual discount rate."
According to the news reporters, the research concluded: "These results suggest that AP80978 has the potential to be optimized into an effective antiviral drug and is a useful tool to further study the role of NS4B in HCV replication."
The key element of the new regimens is that they do not use interferon, "which does have delivery issues as well as adverse effects" Majumdar told MedPage Today
"The efficacy and safety of 24 weeks of daclatasvir plus asunaprevir represents a huge improvement on the first generation of protease inhibitor-based triple therapies for HCV genotype 1b infection (up to 48 weeks of boceprevir or telaprevir in combination with PEG/RBV)."

More Content

All (56) | News (43) | Reports (0) | Blogs (11) | Audio/Video (0) | Fact Sheets (1) | Press Releases (0)
sort by: Date | Relevance
Incivek expected to be discontinued by October [Published Orthopedics Today - Aug 16 2014]
Interactions with Hepatitis C Antivirals [Published Pharmacy Times - Aug 15 2014]
East Coast Biotech Roundup: Amicus, Accelerator... [Published Xconomy - Aug 15 2014]
NICE U-turn on Sovaldi [Published Pharmafocus - Aug 15 2014]
Vertex to drop hep C drug Incivek following poo... [Published Pharma Letter - Aug 14 2014]
Vertex ditches its once-stellar hep C drug [Published Pharmafocus - Aug 14 2014]
Vertex Pharmaceuticals to discontinue US sales ... [Published FirstWord Pharma - Aug 13 2014]
Cyclohexane-Fused Octahydroquinolizine Alkaloi... [Published Journal of Organic Chemistry - Aug 13 2014]
Telaprevir resulted in higher SVR in Japanese p... [Published Orthopedics Today - Aug 11 2014]
Cost-effectiveness of sofosbuvir-based triple t... [Published National AIDS Treatment Advocacy Project - Aug 09 2014]
A Hepatitis C Virus Infection Model with Time-V... [Published Plosone.org - Aug 08 2014]
Modeling Viral Evolutionary Dynamics after Tela... [Published Plosone.org - Aug 07 2014]
Recent Studies from Rockefeller University Add ... [Published HispanicBusiness.com - Aug 06 2014]
15 hepatitis C patients die of drug’s side effects [Published The Japan News - Aug 04 2014]
HALLMARK, COSMOS: New HCV regimens show high cu... [Published Orthopedics Today - Aug 04 2014]
Hepatitis C Screening Beyond CDC Guidelines [Published General Medicine eJournal - Aug 01 2014]
15 Deaths During Use Of Hep C Drug Telavic Sinc... [Published Health News Daily - Jul 31 2014]
Preventing Mortality in Patients With Cirrhosis... [Published Diabetes Care - Jul 31 2014]
Lack of Clinically Relevant Drug Interactions B... [Published National AIDS Treatment Advocacy Project - Jul 31 2014]
New study identifies potential alternatives to ... [Published Pharma Letter - Jul 29 2014]
Hepatitis C Therapeutics Market - Global Indust... [Published MyNewsDesk - Jul 29 2014]
Hepatitis C Therapy in Elderly Patients [Published Diabetes Care - Jul 29 2014]
3D Hepatitis C Combo Effective in HIV Patients [Published EverydayHealth.com - Jul 29 2014]
New therapies for HCV create better alternative... [Published Orthopedics Today - Jul 28 2014]
New pills can help cure hepatitis C [Published The Freepress Journal - Jul 28 2014]
Medical News Today: Studies reveal success of n... [Published Medical News Today - Jul 28 2014]
The Lancet: New oral drug regimens cure hardest... [Published EurekAlert! - Jul 27 2014]
NHS England's Sovaldi fund: opening the floodga... [Published Pharmafocus - Jul 27 2014]
The Hepatitis C virus is the main cause of live... [Published Bio-Medicine - Jul 25 2014]
The Hepatitis C virus is the main cause of live... [Published BioPortfolio - Jul 25 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
The Hepatitis C virus is the main cause of live... [Published PR Newswire: General Business - Jul 25 2014]
PORT OF SPAIN, Trinidad and Tobago, July 25, 2014 /PRNewswire/ -- The Chemistry, Food & Drugs Division of the Trinidad & Tobago Ministry of Health approved the introduction of Telaprevir to the market, an innovative therapy that significantly increases ...
Treating Hepatitis C: Criticisms of sofosbuvir [Published The Incidental Economist (Posts) - Jun 17 2014]
The following is part of a series of guest posts on hepatitis C by Allan Joseph, a medical student at the Warren Alpert Medical School of Brown University and TIE research assistant. You can follow Allan on Twitter:  @allanmjoseph . Links to all posts ...
Treating Hepatitis C: Sofosbuvir [Published The Incidental Economist (Posts) - Jun 16 2014]
The following is part of a series of guest posts on hepatitis C by Allan Joseph, a medical student at the Warren Alpert Medical School of Brown University and TIE research assistant. You can follow Allan on Twitter:  @allanmjoseph . Links to all posts ...
Treating hepatitis C: Treatment options before ... [Published The Incidental Economist (Posts) - Jun 13 2014]
The following is part of a series of guest posts on hepatitis C by Allan Joseph, a medical student at the Warren Alpert Medical School of Brown University and TIE research assistant. You can follow Allan on Twitter:  @allanmjoseph . Links to all posts ...
Treatment of HCV with ABT-450/r–Ombitasvir and ... [Published NEJM Articles Most Widely Covered in the Press - Apr 28 2014]
Approximately 184 million people worldwide have chronic hepatitis C virus (HCV) infection, and more than 350,000 people die of HCV-related liver disease each year.1,2 Until recently, the standard of care for chronic HCV genotype 1 infection was a first-generation ...
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.